BTOG 2024 | Key insights from BTOG 2024: MARS 2 and HIT-MESO

At the BTOG 2024 congress in Belfast, UK, Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, London, UK, discusses key presentations from the event. He highlights the MARS 2 trial (NCT02040272), led by Prof. Eric Lim, which revealed inferior survival associated with interventional surgery in a randomized context, sparking debate among thoracic oncology professionals. Dr Shah notes robust defense of the trial’s data by Lim, despite criticisms. He also discusses a radiotherapy study presented by Dr Crispin Hiley, focusing on the potential role of proton therapy in managing mesothelioma patients. The HIT-MESO trial (NCT05655078), recently launched in the UK, aims to assess ablative doses of proton therapy’s impact on overall survival, a complex yet promising endeavor expected to run for several years. This interview took place at the BTOG 2024 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.